TY - JOUR
T1 - Catheter ablation for persistent atrial fibrillation
T2 - A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study
AU - Chieng, David
AU - Sugumar, Hariharan
AU - Ling, Liang Han
AU - Segan, Louise
AU - Azzopardi, Sonia
AU - Prabhu, Sandeep
AU - Al-Kaisey, Ahmed
AU - Voskoboinik, Aleksandr
AU - Parameswaran, Ramanathan
AU - Morton, Joseph B.
AU - Pathik, Bhupesh
AU - McLellan, Alex J.
AU - Lee, Geoffrey
AU - Wong, Michael
AU - Finch, Sue
AU - Pathak, Rajeev K.
AU - Raja, Deep Chandh
AU - Sanders, Prashanthan
AU - Sterns, Laurence
AU - Ginks, Matthew
AU - Reid, Christopher M.
AU - Kalman, Jonathan M.
AU - Kistler, Peter M.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Background: The success of pulmonary vein isolation (PVI) is reduced in persistent AF (PsAF) compared to paroxysmal AF. Adjunctive ablation strategies have failed to show consistent incremental benefit over PVI alone in randomized studies. The left atrial posterior wall is a potential source of non-PV triggers and atrial substrate which may promote the initiation and maintenance of PsAF. Adding posterior wall isolation (PWI) to PVI had shown conflicting outcomes, with earlier studies confounded by methodological limitations. Objectives: To determine whether combining PWI with PVI significantly improves freedom from AF recurrence, compared to PVI alone, in patients with PsAF. Methods: This is a multi-center, prospective, international randomized clinical trial. 338 patients with symptomatic PsAF refractory to anti-arrhythmic therapy (AAD) will be randomized to either PVI alone or PVI with PWI in a 1:1 ratio. PVI involves wide antral circumferential pulmonary vein (PV) isolation, utilizing contact force sensing ablation catheters. PWI involves the creation of a floor line connecting the inferior aspect of the PVs, and a roof line connecting the superior aspect of the PVs. Follow up is for a minimum of 12 months with rhythm monitoring via implantable cardiac device and/or loop monitor, or frequent intermittent monitoring with an ECG device. The primary outcome is freedom from any documented atrial arrhythmia of > 30 seconds off AAD at 12 months, after a single ablation procedure. Conclusions: This randomized study aims to determine the success and safety of adjunctive PWI to PVI in patients with persistent AF.
AB - Background: The success of pulmonary vein isolation (PVI) is reduced in persistent AF (PsAF) compared to paroxysmal AF. Adjunctive ablation strategies have failed to show consistent incremental benefit over PVI alone in randomized studies. The left atrial posterior wall is a potential source of non-PV triggers and atrial substrate which may promote the initiation and maintenance of PsAF. Adding posterior wall isolation (PWI) to PVI had shown conflicting outcomes, with earlier studies confounded by methodological limitations. Objectives: To determine whether combining PWI with PVI significantly improves freedom from AF recurrence, compared to PVI alone, in patients with PsAF. Methods: This is a multi-center, prospective, international randomized clinical trial. 338 patients with symptomatic PsAF refractory to anti-arrhythmic therapy (AAD) will be randomized to either PVI alone or PVI with PWI in a 1:1 ratio. PVI involves wide antral circumferential pulmonary vein (PV) isolation, utilizing contact force sensing ablation catheters. PWI involves the creation of a floor line connecting the inferior aspect of the PVs, and a roof line connecting the superior aspect of the PVs. Follow up is for a minimum of 12 months with rhythm monitoring via implantable cardiac device and/or loop monitor, or frequent intermittent monitoring with an ECG device. The primary outcome is freedom from any documented atrial arrhythmia of > 30 seconds off AAD at 12 months, after a single ablation procedure. Conclusions: This randomized study aims to determine the success and safety of adjunctive PWI to PVI in patients with persistent AF.
UR - http://www.scopus.com/inward/record.url?scp=85122488088&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2021.09.015
DO - 10.1016/j.ahj.2021.09.015
M3 - Article
SN - 0002-8703
VL - 243
SP - 210
EP - 220
JO - American Heart Journal
JF - American Heart Journal
ER -